In other words, the price has increased by $0.0000 from its previous closing price. On the day, 632823 shares were traded.
For a deeper understanding of Vanda Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.67. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.32. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 25, 2022, Downgraded its rating to Hold and sets its target price to $12 from $24 previously.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 21 when Wijkstrom Joakim sold 3,724 shares for $5.84 per share. The transaction valued at 21,748 led to the insider holds 113,816 shares of the business.
Mitchell Stephen Ray sold 6,500 shares of VNDA for $39,349 on Aug 10. The Director now owns 29,328 shares after completing the transaction at $6.05 per share. On Jul 28, another insider, Moran Kevin Patrick, who serves as the SVP, CFO & Treasurer of the company, sold 2,212 shares for $6.30 each. As a result, the insider received 13,945 and left with 120,714 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNDA now has a Market Capitalization of 196.10M and an Enterprise Value of -283.91M. As of this moment, Vanda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.93 while its Price-to-Book (P/B) ratio in mrq is 0.36. Its current Enterprise Value per Revenue stands at -1.34 whereas that against EBITDA is -124.19.
Stock Price History:
Over the past 52 weeks, VNDA has reached a high of $11.04, while it has fallen to a 52-week low of $3.30. The 50-Day Moving Average of the stock is 4.4064, while the 200-Day Moving Average is calculated to be 5.9190.
For the past three months, VNDA has traded an average of 1.25M shares per day and 930.56k over the past ten days. A total of 56.78M shares are outstanding, with a floating share count of 55.56M. Insiders hold about 3.40% of the company’s shares, while institutions hold 97.55% stake in the company. Shares short for VNDA as of Oct 30, 2023 were 1.68M with a Short Ratio of 1.68M, compared to 1.51M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.93% and a Short% of Float of 3.69%.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.00%, it implies a Forward Annual Dividend Yield of 5.72%.
There are 1 different market analysts currently analyzing its stock. On average, analysts expect EPS of $-0.09 for the current quarter, with a high estimate of $-0.09 and a low estimate of $-0.09, while EPS last year was $0.06. The consensus estimate for the next quarter is $-0.08, with high estimates of $-0.08 and low estimates of $-0.08.
Analysts are recommending an EPS of between $-0.01 and $-0.01 for the fiscal current year, implying an average EPS of $-0.01. EPS for the following year is $-0.46, with 1 analysts recommending between $-0.46 and $-0.46.
A total of 1 analysts believe the company’s revenue will be $37M this quarter.It ranges from a high estimate of $37M to a low estimate of $37M. As of the current estimate, Vanda Pharmaceuticals Inc’s year-ago sales were $64.48M, an estimated decrease of -42.60% from the year-ago figure.
A total of 1 analysts have provided revenue estimates for VNDA’s current fiscal year. The highest revenue estimate was $184.4M, while the lowest revenue estimate was $184.4M, resulting in an average revenue estimate of $184.4M. In the same quarter a year ago, actual revenue was $254.38M, down -27.50% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $148.5M in the next fiscal year. The high estimate is $148.5M and the low estimate is $148.5M. The average revenue growth estimate for next year is down -19.50% from the average revenue estimate for this year.